Alex Biese

Articles

Race Is Predictive of Survival Outcomes With Intensive Chemotherapy Independent of Cytogenetics in AML

December 6th 2025

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Families Face Financial Hardships in Pediatric ALL

December 6th 2025

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

Real-World Data Shows Vorasidenib Could Address Earlier Treatment Needs in IDH-Mutant Glioma

November 29th 2025

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Vorasidenib Demonstrates Favorable Safety Profile and Disease Stability in High-Grade IDH-Mutant Gliomas

November 27th 2025

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

Vorasidenib Shows Rapid Real-World Uptake in IDH-Mutated Glioma

November 24th 2025

Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

IO102-IO103 Plus Pembrolizumab Improves PFS in Treatment-Naive Advanced Melanoma

October 20th 2025

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.

Transdermal Estradiol Plus ARPIs Demonstrate Comparable PSA Response to LHRHa in Metastatic Prostate Cancer

February 14th 2025

Responses were similar among patients with estrogen patches and ARPIs compared to aLHRH and ARPIs in metastatic prostate cancer.

A “Rock Star” in Patient-Reported Outcomes, Is Listening

January 2nd 2025

Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.

Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer

December 19th 2024

Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.

Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo

December 12th 2024

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis

December 10th 2024

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies

December 10th 2024

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL

December 10th 2024

Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 10th 2024

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

November 16th 2024

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Adagrasib Is Superior to Docetaxel in Pretreated KRAS G12C–Mutated NSCLC

September 14th 2024

The benefits of adagrasib over docetaxel were seen regardless of baseline brain metastases, according to findings presented at ESMO.

Neoadjuvant Endocrine Therapy Plus Trastuzumab/Pertuzumab Yields Comparable Survival in HR+/HER2+ Early Breast Cancer

September 14th 2024

Neoadjuvant endocrine therapy or paclitaxel combined with trastuzumab and pertuzumab achieved notable survival benefits in HR-positive, HER2-positive early breast cancer.

TILs May Prognosticate Survival Benefit With Treatment De-escalation in Early HER2+ Breast Cancer

September 14th 2024

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer

June 2nd 2024

The delivery of palliative care through telehealth vs in-person visits was equally beneficial for patients with advanced non–small cell lung cancer.